GSK
GSK plc
- PER (TTM)
- 13.06
- PER (Forward)
- 9.63
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 4.18
- 시가총액
- 101.20B
- 배당수익률
- 357.00%
- 베타
- 0.30
- 1개월 수익률
- -13.62%
- 3개월 수익률
- -15.63%
- 6개월 수익률
- 9.79%
- 1년 수익률
- 41.04%
- 2년 수익률
- -
- 5일 평균거래량
- 3286960
- 60일 평균거래량
- 4681340
- 1년 평균거래량
- 4915654
- 5d/60d 거래량 비율
- 0.70×
- 60d/1y 거래량 비율
- 0.95×
- 변동성(60일, 연환산)
- 25.58%
- BB 스퀴즈 스코어
- 1.75
- SMA50 비율
- 0.92
- SMA200 비율
- 1.05
- RSI (14)
- 31
- 20일 수렴도
- 0.06
- 52주 최고
- 60.69
- 52주 최저
- 34.83
- 고점 대비
- -16.94%
- 저점 대비
- 44.74%
펀더멘털 갱신: 2026-05-10T09:17:39+00:00 · 시세 갱신: 2026-05-10T06:39:06+00:00
회사 정보
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.